In dry eye disease (DED), the normal functioning of the tear film is disrupted, resulting in troublesome ocular symptoms such as eye burning, and presenting with typical signs such as reduced tear production. Few drugs are approved in the U.S. market for managing DED; AbbVie’s (earlier Allergan) blockbuster Restasis enjoyed the status of the only therapy approved for this indication for more than a decade until the launch of Novartis’s Xiidra in 2016, the newer Restasis MultiDose formulation in 2017, and Sun Ophthalmics’ Cequa in 2019. In addition to these approved drugs, other pharmacotherapies, such as topical corticosteroids, are commonly prescribed to treat DED. This content provides manufacturers of current treatments, as well as those developing novel agents for DED, with real-world insights regarding recent trends in the use of drugs in this indication.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Geographies: United States
Real world data: Longitudinal patient-level claims data analysis
Key drugs covered: Restasis, Restasis MultiDose, Xiidra, corticosteroids (ophthalmic), antibiotics (oral and ophthalmic)
Key analysis provided:
Brand / therapy usage across longitudinal patient sample.
Newly diagnosed patient analysis.
Treatment initiation and progression.
Line of therapy analysis.
Combination therapy analysis.
Source of business for recently treated patients.
Persistency and compliance analysis.
Product-level patient flowcharts.
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.